Cost-Effective Analysis of Aspirin and Clopidogrel Therapy in Hospitalized Ischemic Stroke Patients at Mataram City Hospital

Akhmad Nurfahmi; Lucia Vita Inandha Dewi; Gunawan Pramudji Widodo

doi:10.55927/fjst.v5i2.17

Authors

Akhmad Nurfahmi Pharmacy Study Program, Faculty of Pharmacy, Setia Budi University, Central Java
Lucia Vita Inandha Dewi Pharmacy Study Program, Faculty of Pharmacy, Setia Budi University, Central Java
Gunawan Pramudji Widodo Pharmacy Study Program, Faculty of Pharmacy, Setia Budi University, Central Java

DOI:

https://doi.org/10.55927/fjst.v5i2.17

Keywords:

Cost Effectiveness Analysis; Ischemic stroke; Mataram City Hospital.

Abstract

Ischemic stroke is one of the diseases with the highest death cases in Indonesia. So stroke patients often need further treatment and long-term rehabilitation. To determine the cost-effectiveness and therapy of aspirin and clopidogrel in ischemic stroke patients by looking at the GCS score of hospitalization at Mataram City Hospital, and to determine the most cost-effective therapy based on ACER and ICER. The research method used was observational descriptive and data collection was carried out retrospectively through patient medical records and financial details data. The sample met the inclusion criteria of 78 people, the sample was analyzed quantitatively by the Independent sample t-test analysis method. The results showed that the total cost of treatment for ischemic stroke patients treated with antiplatelets was the highest in the VIP class clopidogrel group of Rp 5,400,015 and VIP class aspirin Rp 4,982,370 The increase in the highest GCS score of aspirin in class ll was 2.84 and clopidogrel class lll was 2.45. The most cost-effective ACER values of all antiplatelet treatment classes are aspirin VIP class Rp 2,129,218, class l Rp 1,785,451, class ll Rp 1,700,509, class lll Rp 1,380,574 and ICER value in class l Rp -1,993,315 and class lll Rp -1,555,950. The ACER scores of all treatment classes showed that aspirin had the lowest scores. Based on sensitivity analysis and tornado diagrams, clopidogrel showed higher results so that aspirin was more cost-effective than clopidogrel. The use of aspirin antiplatelets was more cost-effective than clopidogrel from all direct medical cost data of ischemic stroke patients

References

Fatin, M. N. A., Rahayu, C., & Suwantika, A. A. (2019). Analisis Efektivitas Biaya Penggunaan Antibiotik pada Pasien Community-acquired Pneumonia di RSUP Dr. Hasan Sadikin Bandung. Indonesian Journal of Clinical Pharmacy, 8(3). https://doi.org/10.15416/ijcp.2019.8.3.228

Kementrian Kesehatan RI, (2018). Laporan Nasional RISKESDAS 2018.

Mutiarasari, D. (2019). Ischemic Stroke: Symptoms, Risk Factors, and Prevention. Jurnal Ilmiah Kedokteran Medika Tandulako, 1(1), 60–73.

Ojaghihaghighi, S., Vahdati, S. S., Mikaeilpour, A., & Ramouz, A. (2017). Comparison of neurological clinical manifestation in patients with hemorrhagic and ischemic stroke. World Journal of Emergency Medicine, 8(1), 34. https://doi.org/10.5847/wjem.j.1920-8642.2017.01.006

Pichon-Riviere, A., Drummond, M., Palacios, A., Garcia-Marti, S., & Augustovski, F. (2023). Determining the efficiency path to universal health coverage: cost-effectiveness thresholds for 174 countries based on growth in life expectancy and health expenditures. The Lancet Global Health, 11(6), e833–e842. https://doi.org/10.1016/S2214-109X(23)00162-6

Powers, W. J., Rabinstein, A. A., Ackerson, T., Adeoye, O. M., Bambakidis, N. C., Becker, K., Biller, J., Brown, M., Demaerschalk, B. M., Hoh, B., Jauch, E. C., Kidwell, C. S., Leslie-Mazwi, T. M., Ovbiagele, B., Scott, P. A., Sheth, K. N., Southerland, A. M., Summers, D. V., & Tirschwell, D. L. (2018). 2018 Guidelines for the Early Management of Patients With Acute Ischemic Stroke: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association. In Stroke (Vol. 49, Issue 3).

Rakhmawati, N., Paryono, & Setyaningsih, I. (2019). Resistensi Antiplatelet pada Stroke Iskemik. Berkala Neurosains, 18(1), 1–7.

Refasi, N. L., Lolo, W. A., & Bodhi, W. (2018). Analisis Efektivitas Biaya (Cost Effectiveness Analysis) pada Pengobatan Pasien Malaria Falciparum di RSUD Nabire. Pharmacon, 7(2), 1–9.

Sultradewi Kesuma, N. M. T., Krismashogi Dharmawan, D., & Fatmawati, H. (2019). Gambaran faktor risiko dan tingkat risiko stroke iskemik berdasarkan stroke risk scorecard di RSUD Klungkung. Intisari Sains Medis, 10(3), 720–729. https://doi.org/10.15562/ism.v10i3.397

Ulfah, U., Halimah, E., & Suwantika, A. A. (2022). Analisis Efektivitas Biaya Pasien PROLANIS DM Tipe 2 di Puskesmas Kota Bandung. Jurnal Sains Dan Kesehatan, 4(1), 19–27. https://doi.org/10.25026/jsk.v4i1.76

Wajngarten, M., & Silva, G. S. (2019). Ischaemic Heart Disease , Stroke and Risk Factors Hypertension and Stroke : Update on Treatment Ischaemic Heart Disease , Stroke and Risk Factors. Radcliffe Cardiology, 14(2), 111–115.

Wuysang, D. B. A. (2015). Pemeriksaan derajat kesadaran (glasgow coma scale) dan fungsi kortikal luhur (mini-mental state examination (mmse). Departemen Neurologi Fakultas Kedokteran Universitas Hasanuddi, 5-10.